5,237 Shares in IDEXX Laboratories, Inc. $IDXX Acquired by Bell Asset Management Ltd

Key Points

• Bell Asset Management acquired 5,237 IDEXX Laboratories shares worth approximately $2.74 million during the third quarter. Institutional investors collectively own 87.84% of the company, while insiders own 0.79%.
• Analyst sentiment remains generally positive, with six Buy ratings and four Hold ratings producing a “Moderate Buy” consensus and an average price target of $747.00.
• IDEXX reported quarterly EPS of $4.27, beating estimates of $3.94, while revenue rose 9.7% year over year to $1.22 billion. The company reaffirmed fiscal 2026 EPS guidance of $14.69–$14.94.

Bell Asset Management Ltd bought a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 5,237 shares of the company's stock, valued at approximately $2,735,000.

Several other large investors have also recently made changes to their positions in IDXX. J. Stern & Co. LLP boosted its stake in IDEXX Laboratories by 23,694.7% during the 4th quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company's stock worth $1,795,072,000 after purchasing an additional 2,642,200 shares during the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of IDEXX Laboratories in the second quarter valued at approximately $628,223,000. Arrowstreet Capital Limited Partnership increased its holdings in shares of IDEXX Laboratories by 197.3% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 550,368 shares of the company's stock valued at $372,340,000 after purchasing an additional 365,274 shares during the last quarter. Alyeska Investment Group L.P. increased its holdings in shares of IDEXX Laboratories by 97.3% in the second quarter. Alyeska Investment Group L.P. now owns 401,082 shares of the company's stock valued at $211,146,000 after purchasing an additional 197,808 shares during the last quarter. Finally, Montrusco Bolton Investments Inc. lifted its position in IDEXX Laboratories by 93.4% during the first quarter. Montrusco Bolton Investments Inc. now owns 342,120 shares of the company's stock worth $186,707,000 after buying an additional 165,188 shares in the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director Lawrence D. Kingsley sold 2,203 shares of the business's stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $532.08, for a total value of $1,172,172.24. Following the sale, the director directly owned 9,568 shares in the company, valued at approximately $5,090,941.44. The trade was a 18.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.79% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Citigroup upped their target price on IDEXX Laboratories from $650.00 to $670.00 and gave the company a "neutral" rating in a report on Wednesday, August 5th. UBS Group lifted their price target on IDEXX Laboratories from $620.00 to $670.00 and gave the stock a "neutral" rating in a report on Wednesday, August 5th. Barclays lowered their price target on shares of IDEXX Laboratories from $800.00 to $710.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 11th. Weiss Ratings lowered shares of IDEXX Laboratories from a "hold (c+)" rating to a "hold (c)" rating in a report on Thursday, August 27th. Finally, Wall Street Zen cut shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Sunday, July 12th. Six investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, IDEXX Laboratories currently has an average rating of "Moderate Buy" and an average target price of $747.00.

IDEXX Laboratories Trading Up 1.3%

Shares of IDEXX Laboratories stock opened at $513.14 on Friday. The firm has a market capitalization of $40.43 billion, a price-to-earnings ratio of 36.09, a PEG ratio of 2.70 and a beta of 1.55. IDEXX Laboratories, Inc. has a fifty-two week low of $500.61 and a fifty-two week high of $769.98. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.17. The stock has a 50 day moving average of $539.78 and a 200 day moving average of $553.31.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, beating analysts' consensus estimates of $3.94 by $0.33. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The company had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.20 billion. During the same quarter in the previous year, the business earned $3.50 earnings per share. The company's revenue for the quarter was up 9.7% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, research analysts predict that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc NASDAQ: IDXX develops and provides diagnostic, information technology and water-testing products and services. The company primarily serves the companion animal veterinary market, helping veterinary practices diagnose and manage diseases through laboratory testing, in-house analyzers, diagnostic kits, imaging systems, software and related consumables.

IDEXX's companion animal offerings include its IDEXX Reference Laboratories, IDEXX VetLab instruments and software, SNAP rapid tests, and practice-management and data solutions.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.